Photo of Emma Guttman

Emma Guttman

  • PROFESSOR Dermatology
  • PROFESSOR (PENDING) Medicine, Clinical Immunology
Print ProfilePrint Profile



  • American Board of Dermatology

Clinical Focus


  • MD, Sackler School of Medicine

  • Internship, Rotating
    Meir Hospital

  • Residency, Dermatology
    Rambam Health Care Campus

  • Internship, Internal Medicine
    Memorial Sloan-Kettering Cancer Center

  • Residency, Dermatology
    Weill Cornell Medical College


    Emma Guttman-Yassky, MD, PhD is a Professor of Dermatology & Immunology and Director of the center for Excellence in Eczema , the Occupational/Contact Dermatitis clinic, and the Director of the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center in New York. She earned her M.D. degree from Sackler School of Medicine at the Tel-Aviv University, and a Ph.D. degree from the Bar-Ilan University Ramat-Gan, Israel. Dr. Guttman completed her first dermatology residency at the Dermatology Department at the Rambam Medical Center/Technion Institute in Haifa. After obtaining her Israeli Board certification in dermatology, Dr. Guttman moved to the U.S. to pursue a two-year postdoctoral fellowship at The Rockefeller University in the Laboratory for Investigative Dermatology. Upon completion of her fellowship, she became board-certified by the American Board of dermatology after obtaining her second dermatology residency training at the Weill-Cornell Medical College, in NY. Dr. Guttman’s major clinical focus is atopic dermatitis (AD)/eczema, contact/occupational dermatitis, alopecia areata, and psoriasis. She has done groundbreaking research and published extensively on inflammatory skin diseases. Her research made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis (AD) in humans, enriching the understanding of the pathophysiology of this common disorder, opening the door to new therapeutics.  Dr. Guttman has developed comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease. She has established the reversibility of the AD phenotype and defined a series of disease- and response- biomarkers that are now accelerating testing of novel immune, pathway-specific drugs in this disease. Her research is the first to identify in humans a distinct population of T-cells that independently produce IL-22, conceptualizing AD as a Th2/Th22-polarized disease. Dr Guttman is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis. She has recently also extended her research interest to alopecia areata in which her findings are also translated to possible novel therapeutic targets. Together with Dr. Amy Paller she founded the international eczema council (IEC), for which she functions as president elect. Dr Guttman was (2015) elected as a member to the American Society for Clinical Investigation (ASCI), as well as the American Dermatological Society (ADA), and is the recipient of the prestigious Young Investigator Award (2011) from the American Academy of Dermatology (AAD). She also received the Dermatology Foundation’s Physician-Scientist Career Development Award, and the Everett C. Fox Award for best clinical research at the Residents & Fellows Symposium of the AAD. Dr. Guttman has been awarded several federal and foundation grants. She received a large NIH grant to do a proof of concept study on the role of Th22 T-cells in atopic dermatitis/eczema using a novel anti IL-22 antibody. She has also secured a grant from the LEO Foundation to study immune and terminal differentiation biomarkers in pediatric AD, as well as an

    award from the National Institute of Allergy and Infectious Diseases (NIAID)

    to participate in a multi-center study on the role of infections in AD.

    Additionally, she received support from pharmaceutical companies, underscoring her recognition as an outstanding physician-scientist in the dermatology community. She is doing many mechanistic studies involving clinical trials with new therapeutics in patients atopic dermatitis around the globe. Her research on eczema has contributed directly to the recently developed treatments for this disease, earning her a unique place in dermatology and immunology worldwide. She is now invited to speak and chair symposia not only nationally, but also in Europe and Japan on novel developments in AD and its therapeutics.



  • 2011 -
    Young Investigator Award (2011)
    American Academy of Dermatology


Inflammatory Skin Diseases

st1:*{behavior:url(#ieooui) }

Dr. Guttman’s groundbreaking research focuses on atopic dermatitis/eczema and contact dermatitis. Her research has important implications in advancing the current molecular knowledge on atopic dermatitis/eczema and developing new therapeutics.

Dr. Guttman currently develops biomarkers of atopic dermatitis that could be used for future studies with targeted therapeutics. She also concentrates on unraveling the primary pathogenesis of this common disease.

st1:*{behavior:url(#ieooui) }

She is the recipient of the prestigious Young Investigator Award (2011) from the of Dermatology, the 2011 recipient of the Dermatology Foundation’s Physician-Scientist Career Development Award, and the recipient of the Fisher award of the American Contact Dermatitis Society 2011.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Guttman during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Bristol-Myers Squibb; Celgene Corporation; Celsus Therapeutics Plc; Dermira; Eli Lilly and Company; Galderma S.A.; Novartis Pharma AG; Pfizer Inc.; Regeneron Pharmaceuticals; Stiefel Laboratories, Inc., a GSK company

Scientific Advisory Board:

  • Anacor Pharmaceuticals, Inc.; Glenmark Generics Inc. (GGI), USA, formerly Glenmark Pharmaceuticals Inc.; MedImmune, LLC; Pfizer Inc.; sanofi-aventis

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.

  • Dermira; MedImmune, LLC; Stiefel Laboratories, Inc., a GSK company

Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:

  • Stiefel Laboratories, Inc., a GSK company

Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.

  • LEO Pharma A/S; Merck & Co., Inc.; Regeneron Pharmaceuticals

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Faculty Practice Associates Floor 5th Room Dermatology Suite
5 East 98th Street
New York, NY 10029

Tel: 212-241-9728


Annenberg Building Floor 11th
1468 Madison Avenue
New York, NY 10029

Mount Sinai Dermatology Faculty Practice Associate

5 East 98 Street
5th Floor, Dermatology Suite
New York, NY 10029

Tel: 212-241-9728
Fax: 212-241-6690
Get Directions

Office Hours:
  • Monday 8:00am - 5:00pm
  • Wednesday 8:00am - 1:00pm
  • Thursday 8:00am - 1:00pm
  • Hebrew
  • Romanian
  • Russian
  • Spanish
Insurance Plans
  • 1199
  • Aetna
  • CIGNA Select Source
  • Oxford Freedom
  • Oxford Health Plans
  • Oxford Health Plans - HMO
  • Oxford Health Plans of New York
  • United Health - PPO
  • United Healthcare - HMO
  • United Healthcare - Mount Sinai Top Tier
  • United Healthcare Empire Plan
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash